Information Provided By: 
Fly News Breaks for July 18, 2016
RARE
Jul 18, 2016 | 08:04 EDT
SunTrust says that the data for Ultragenyx's mGUS drug was "largely successful," with "very robust and consistent" efficacy on the primary endpoint. The firm says that the EU will very likely approve the drug, while U.S. approval "seems slightly questionable, but remains quite promising." The firm reiterates a $100 price target and Buy rating on the shares.
News For RARE From the Last 2 Days
